2,460 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Acquired by KPP Advisory Services LLC

KPP Advisory Services LLC purchased a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) in the 3rd quarter, HoldingsChannel.com reports. The fund purchased 2,460 shares of the biopharmaceutical company’s stock, valued at approximately $206,000.

A number of other hedge funds have also recently made changes to their positions in GILD. Natixis Advisors LLC grew its position in Gilead Sciences by 18.1% during the third quarter. Natixis Advisors LLC now owns 169,363 shares of the biopharmaceutical company’s stock worth $14,199,000 after buying an additional 25,912 shares in the last quarter. Coastline Trust Co bought a new stake in shares of Gilead Sciences during the 3rd quarter valued at about $122,000. Simplify Asset Management Inc. bought a new stake in shares of Gilead Sciences during the 3rd quarter valued at about $8,066,000. KCM Investment Advisors LLC grew its holdings in shares of Gilead Sciences by 3.2% during the third quarter. KCM Investment Advisors LLC now owns 9,096 shares of the biopharmaceutical company’s stock worth $763,000 after purchasing an additional 282 shares in the last quarter. Finally, Archer Investment Corp increased its position in shares of Gilead Sciences by 25.3% in the third quarter. Archer Investment Corp now owns 7,190 shares of the biopharmaceutical company’s stock worth $603,000 after purchasing an additional 1,454 shares during the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on GILD shares. Leerink Partners raised shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and boosted their price target for the stock from $74.00 to $96.00 in a research note on Monday, October 21st. Royal Bank of Canada increased their target price on Gilead Sciences from $75.00 to $81.00 and gave the company a “sector perform” rating in a research note on Thursday, November 7th. Piper Sandler lifted their price target on Gilead Sciences from $95.00 to $105.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. Maxim Group lowered Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Friday, November 8th. Finally, BMO Capital Markets boosted their target price on Gilead Sciences from $94.00 to $102.00 and gave the stock an “outperform” rating in a research report on Thursday, November 7th. Eleven research analysts have rated the stock with a hold rating, eleven have given a buy rating and four have assigned a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $93.86.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 29,357 shares of the firm’s stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the completion of the transaction, the insider now owns 78,127 shares of the company’s stock, valued at approximately $6,545,480.06. This trade represents a 27.31 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $83.83, for a total transaction of $167,660.00. Following the transaction, the insider now owns 100,189 shares of the company’s stock, valued at $8,398,843.87. The trade was a 1.96 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 56,947 shares of company stock worth $4,968,674 over the last ninety days. 0.16% of the stock is owned by corporate insiders.

Gilead Sciences Trading Down 4.0 %

NASDAQ GILD opened at $88.40 on Friday. The company has a debt-to-equity ratio of 1.24, a quick ratio of 0.82 and a current ratio of 1.26. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $98.90. The stock has a market cap of $110.17 billion, a P/E ratio of 982.22, a price-to-earnings-growth ratio of 2.85 and a beta of 0.17. The stock has a 50 day simple moving average of $86.68 and a two-hundred day simple moving average of $76.04.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, topping the consensus estimate of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The firm had revenue of $7.55 billion during the quarter, compared to analysts’ expectations of $7.01 billion. During the same period last year, the company posted $2.29 EPS. The company’s quarterly revenue was up 7.0% compared to the same quarter last year. On average, analysts forecast that Gilead Sciences, Inc. will post 4.39 earnings per share for the current year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 30th. Stockholders of record on Friday, December 13th will be paid a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.48%. The ex-dividend date is Friday, December 13th. Gilead Sciences’s payout ratio is presently 3,422.22%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.